1.
Am J Hematol
; 99(2): E32-E36, 2024 Feb.
Article
in English
| MEDLINE
| ID: mdl-37994196
ABSTRACT
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.
Subject(s)
Antibodies, Monoclonal , Leukemia, Myeloid, Acute , Leukemia, Myelomonocytic, Chronic , Myelodysplastic Syndromes , Humans , Azacitidine/therapeutic use , Decitabine/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , Myelodysplastic Syndromes/drug therapy , Hepatitis A Virus Cellular Receptor 2/therapeutic use , Leukemia, Myelomonocytic, Chronic/drug therapy , Leukemia, Myeloid, Acute/drug therapy , Antibodies/therapeutic use , Treatment Outcome
2.
Cancer
; 122(8): 1299-300, 2016 Apr 15.
Article
in English
| MEDLINE
| ID: mdl-26882103